Latest filing published 02 Apr 2025 for Intra-Cellular Therapies, Inc., €5.2M. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Suresh K. Durgam (senior executive) discloses dealings in Intra-Cellular Therapies, Inc. to SEC (Form 4). Over a trading history stretching from 8 January 2022 to 2 April 2025, the count stands at 19 filings.
No open-market purchase appears, only 5 sales worth €2.1M. Outside the open market, there are 2 share grants and 11 option exercises.
The latest filing, published on 2 April 2025, reports a transaction of €5.2M in Intra-Cellular Therapies, Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
19 of 19 declarations